Hematology/Oncology Clinics of North America
- Print ISSN
- Electronic ISSN
- Impact factor
- Usage rank
- Article count
- Free count
- Free percentage
- PDFs via platforms
- Sciencedirect and Mdconsult from 1996
Thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome: an update.
Since the last review in 2007 of thrombotic thrombocytopenic purpura (TTP) and microangiopathic hemolytic anemia in the Clinics, further understanding of the nature of TTP and atypical hemolytic uremic syndrome (aHUS) has led to increasing use of rituximab in the treatment of TTP and the approval in...
Understanding the immunodeficiency in chronic lymphocytic leukemia: potential clinical implications.
Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. Although significant advances have been made in the treatment of CLL in the last decade, it remains incurable. Treatments may be too toxic for some elderly patients, who constitute most of the individuals with this disease, an...
Epidemiology of congenital neutropenia.
Epidemiologic investigations of congenital neutropenia aim to determine several important indicators related to the disease, such as incidence at birth, prevalence, and outcome in the population, including the rate of severe infections, leukemia, and survival. Genetic diagnosis is an important crite...
Parathyroid carcinoma: challenges in diagnosis and treatment.
Parathyroid carcinoma is a malignant neoplasm affecting 0.5% to 5.0% of all patients with primary hyperparathyroidism. Since it was first described by De Quervain in 1904 to this day, it continues to defy diagnosis and treatment because of its rarity, overlapping features with benign parathyroid dis...
Surgical management of cervical carcinoma.
Cervical cancer is the second most common cancer in women worldwide. In developed countries screening programs have decreased the incidence of this disease and improved the detection of early-stage disease amenable to surgical intervention. This article discusses the scope of surgica...
Cellular therapies in acute lymphoblastic leukemia.
I trials at several centers. Treatment of ALL with genetically modified T cells targeted to the CD19 antigen through the expression of a CD19-specific CAR also have entered phase I clinical trials at several centers. Similarly, a clinical trial treating patients with ALL with genetically modified NK...
Chronic myelogenous leukemia. Preface.
Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions.
Insights into the biology of clear-cell renal cell carcinoma (CCRCC) have identified multiple pathways associated with the pathogenesis and progression of this cancer. This progress has led to the development of multiple agents targeting these pathways, including the tyrosine kinase inhibitors soraf...
Management of treatment-related toxicity with targeted therapies for renal cell carcinoma: evidence-based practice and best practices.
The advent of targeted agents for the treatment of advanced renal cell carcinoma has led to dramatic improvements in therapy. However, the chronic use of these medications has also led to the identification of new toxicities that require long-term management. Effective management of toxicity is need...
Pharmacologic induction of fetal hemoglobin production.
Reactivation of fetal hemoglobin (HbF) expression is an important therapeutic option in adult patients with hemoglobin disorders. The understanding of the developmental regulation of γ-globin gene expression was followed by the identification of a number of chemical compounds that can reactivate HbF...